RxDoctor Payments Data

Kayla McCrill

Nurse Practitioner · Sioux City, IANPI 1922671494

Payments from drug & device makers

$891in general payments, 2019–2025

Across 36 payments — averaging $24.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$148
  • Boehringer Ingelheim$134
  • E.r. Squibb & Sons, L.L.C.$119
  • Abbott$110
  • Actelion Pharmaceuticals US, Inc.$99
  • Pfizer$59
  • plus $221 from 9 others

What the payments were for

  • Food & beverage$891100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$891 in reported general payments places this provider in the 80th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$47,481
Medicare patients
697
Services billed
792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban352$240,601
XareltoRivaroxaban133$82,208
JardianceEmpagliflozin47$25,862
FarxigaDapagliflozin Propanediol19$16,964
EntrestoSacubitril/Valsartan21$11,377
BrilintaTicagrelor14$6,067
Metoprolol Succinate524$3,722
Amiodarone Hcl122$2,285
Diltiazem 24hr Er (Cd)Diltiazem Hcl107$1,586
Ezetimibe101$1,483
Ranolazine ErRanolazine30$1,466
Rosuvastatin Calcium220$1,277
SotalolSotalol Hcl140$1,047
Atorvastatin Calcium203$1,009
Isosorbide Mononitrate ErIsosorbide Mononitrate152$664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$59$240,601352 claims
Boehringer IngelheimJardiance$134$25,86247 claims
AstraZenecaFarxiga, Brilinta$29$23,03033 claims
NovartisEntresto$29$11,37721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in Sioux City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →